Stocks · News reference

Reported Earlier, Cullinan Therapeutics And Taiho Partners Announce Phase 3 REZILIENT3 Trial Shows Clinically Meaningful PFS Improvement With Zipalertinib Plus Chemotherapy In EGFR Exon 20 Insertion NSCLC

Aug 13, 2026, 7:21 AMBenzinga Newsdesk

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaAug 19, 2026, 4:11 PMBenzinga Newsdesk
Taiho Oncology And Cullinan Therapeutics Say Results From Planned Interim Analysis Of Phase 3 REZILIENT3 Trial Selected For Presentation In Presidential Symposium 2 At IASLC 2026 World Conference On Lung Cancer
Presentation will feature results from the planned interim analysis of the Phase 3 REZILIENT3 trial, which met its primary endpoint of progression-free survival in first line EGFR exon 20 insertion mutation NSCLCTaiho
Read original at benzinga
CGEM
BenzingaAug 17, 2026, 10:41 AMBenzinga Newsdesk
HC Wainwright & Co. Reiterates Buy on Cullinan Therapeutics, Maintains $30 Price Target
HC Wainwright & Co. analyst Robert Burns reiterates Cullinan Therapeutics (NASDAQ:CGEM) with a Buy and maintains $30 price target.
Read original at benzinga
CGEM
BenzingaAug 13, 2026, 3:21 PMVandana Singh
Cullinan Therapeutics Zipalertinib Combo Clears Key Phase 3 Hurdle As First-Line Lung Cancer Treatment Option Takes Shape
Cullinan Therapeutics and Taiho report positive Phase 3 trial results for zipalertinib in treating advanced lung cancer.
Read original at benzinga
AZN CGEM JNJ
BenzingaAug 13, 2026, 1:02 PMBenzinga Newsdesk
Wedbush Maintains Outperform on Cullinan Therapeutics, Raises Price Target to $42
Wedbush analyst Robert Driscoll maintains Cullinan Therapeutics (NASDAQ:CGEM) with a Outperform and raises the price target from $39 to $42.
Read original at benzinga
CGEM